Citius Pharmaceuticals Secures Funding for LYMPHIR™ Launch in Oncology Market

Citius Oncology Amplifies Financial Backbone for LYMPHIR™ Launch

Citius Oncology, Inc., a notable subsidiary of Citius Pharmaceuticals, Inc., makes a significant stride in securing its financial foundation to support the impending commercial launch of its innovative cancer immunotherapy, LYMPHIR™, aimed at treating cutaneous T-cell lymphoma (CTCL). The company recently announces a definitive agreement with a healthcare-focused investor for a registered direct offering of 1,284,404 shares of common stock priced at $1.09 per share. In addition to the shares, the investor will receive unregistered warrants for an equal number of shares, contingent upon stockholder approval. This strategic financial maneuver is designed to bolster Citius Oncology’s cash reserves, critical for the successful market introduction of LYMPHIR™.

The recent financial activities also encompass a private placement of 15,229,358 shares, or pre-funded warrants, with corresponding warrants at the same price of $1.09 per share. H.C. Wainwright & Co. serves as the exclusive placement agent for these transactions, which are anticipated to yield approximately $18 million in gross proceeds, before expenses. This influx of capital is essential for Citius Oncology not only to facilitate the launch of LYMPHIR™ but also to support general corporate functions and enhance working capital. The closing of these offerings is expected to occur around December 10, 2025, pending customary closing conditions and regulatory approvals.

Citius Oncology’s approach reflects its commitment to advancing its product pipeline and operational capabilities within the oncology sector. By mobilizing funds through these strategic financial offerings, the company positions itself to compete effectively in the rapidly evolving landscape of cancer treatments. The successful launch of LYMPHIR™, which leverages cutting-edge immunotherapy technologies, could significantly enhance treatment options for patients suffering from CTCL, thereby reinforcing Citius Oncology's role in advancing therapeutic innovations within the oncology field.

In addition to these financial developments, the company’s emphasis on research and development remains a cornerstone of its strategy. Citius Oncology continues to explore avenues that enhance its product offerings, positioning itself as a key player in the fight against cancer. The commitment to innovative therapies aligns with the growing demand for effective cancer treatments, spotlighting the potential impact of LYMPHIR™ in the oncology sector.

Overall, Citius Oncology’s recent financial maneuvers not only strengthen its resources but also signal a proactive approach towards fulfilling its mission of improving cancer care through innovative therapies.